Abstract: From a psychological perspective, psychopathology is the area of clinical psychology that has at its core psychological assessment and psychotherapy. In day-to-day clinical practice, psychodiagnosis and psychotherapy are used independently, according to their intended purpose and their specific methods of application. The paper explores how the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and Mini Mental State Examination-2 (MMSE-2) psychological tools contribute to enhancing the effectiveness of cognitive behavioral psychotherapy (CBT). This combined approach, psychotherapy in conjunction with assessment of personality and cognitive functions, is illustrated by two cases, a severe depressive episode with psychotic symptoms and a mixed anxiety-depressive disorder. The order in which CBT, MMPI-2, and MMSE-2 were used in the diagnostic and therapeutic process was determined by the particularities of each case. In the first case, the sequence started with psychotherapy, followed by the administration of blue form MMSE-2, MMPI-2, and red form MMSE-2. In the second case, the cognitive screening with blue form MMSE-2 led to a personality assessment using MMPI-2, followed by red form MMSE-2; reapplication of the MMPI-2 due to the invalidation of the first profile, and finally, psychotherapy. The MMPI-2 protocols gathered useful information that directed the steps of therapeutic intervention: a detailed symptom picture of potentially self-destructive thoughts and behaviors otherwise undetected during the interview. The memory loss and poor concentration were confirmed by MMSE-2 cognitive screening. This combined approach, psychotherapy with psychological assessment, aligns with the trend of adaptation of the psychological services to the everyday life of contemporary man and paves the way for deepening and developing the field.
Abstract: The goal of this paper is to present the diagnostic
contribution that the screening instrument, Mini-Mental State
Examination-2: Expanded Version (MMSE-2:EV), brings in
detecting the cognitive impairment or in monitoring the progress of
degenerative disorders. The diagnostic signification is underlined by
the interpretation of the MMSE-2:EV scores, resulted from the test
application to patients with mild and major neurocognitive disorders.
The cases were selected from current practice, in order to cover vast
and significant neurocognitive pathology: mild cognitive impairment,
Alzheimer’s disease, vascular dementia, mixed dementia, Parkinson’s
disease, conversion of the mild cognitive impairment into
Alzheimer’s disease. The MMSE-2:EV version was used: it was
applied one month after the initial assessment, three months after the
first reevaluation and then every six months, alternating the blue and
red forms. Correlated with age and educational level, the raw scores
were converted in T scores and then, with the mean and the standard
deviation, the z scores were calculated. The differences of raw scores
between the evaluations were analyzed from the point of view of
statistic signification, in order to establish the progression in time of
the disease. The results indicated that the psycho-diagnostic approach
for the evaluation of the cognitive impairment with MMSE-2:EV is
safe and the application interval is optimal. In clinical settings with a
large flux of patients, the application of the MMSE-2:EV is a safe
and fast psychodiagnostic solution. The clinicians can draw objective
decisions and for the patients: it does not take too much time and
energy, it does not bother them and it doesn’t force them to travel
frequently.